Per­cep­tive's fourth — yes, fourth — SPAC jumps to Nas­daq as the blank check tree con­tin­ues to ripen

The biotech SPAC boom has gone al­most hand-in-hand with the in­dus­try’s IPO gold rush, and this week saw more blank check com­pa­nies hop aboard the train.

Lead­ing the way is Per­cep­tive Ad­vi­sors’ fourth SPAC, ap­pro­pri­ate­ly named Arya Sci­ences Ac­qui­si­tion IV, which priced Fri­day morn­ing af­ter rais­ing $130 mil­lion. And on top of that, new Zio­pharm ex­ec­u­tive chair James Huang is launch­ing his own SPAC with MSD Part­ners and Panacea Ven­ture, fil­ing S-1 pa­per­work Thurs­day with plans to raise $200 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA